Alfonso G. Zulueta
Alfonso G. Zulueta is an independent director who joined our Board in January 2022 and is a member of the Nominating and Corporate Governance Committee. Mr. Zulueta has over three decades of experience in global strategic and leadership roles within large pharma, specifically with Eli Lilly and Company (NYSE: LLY). At Eli Lilly, he held key senior positions including Vice President of Global Marketing, President of Global Oncology and Critical Care Products, and most recently as President of International responsible for all geographies outside the United States and Canada from 2017 until his retirement at the end of 2021. He was a corporate officer and member of Eli Lilly and Company’s executive committee.
Mr. Zulueta currently serves on the board of directors of CTS Corporation (NYSE: CTS), a global manufacturer of sensors, connectivity components, and actuators, where he serves on the Audit Committee ; Compensation Committee; and the Nominating, Governance, and Sustainability Committee and on the board of directors of Amarin Corporation (Nasdaq: AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. He also currently serves on the board of directors of Calidi Biotherapeutics, a clinical-stage biotechnology company and Glooko, Inc., a technology company providing personalized remote patient monitoring for diabetes and other related conditions. He also previously served as a member of the board of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and US-Japan Business Council. He received his Bachelor of Arts in Economics from De La Salle University in the Philippines, and his MBA from Colgate Darden Graduate School of Business Administration at the University of Virginia.